No prior pelvic radiation therapy
Patients who have received prior pelvic radiotherapy
Any prior pelvic radiation
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Patients with renal abnormalities requiring modification of radiation field (pelvic kidney, renal transplant, etc.)
Patients who have received previous vaginal, pelvic, or abdominal irradiation
Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields
Patients who have received prior pelvic radiation or cytotoxic chemotherapy
Patients who have received prior prostate or pelvic radiotherapy, including external beam or brachytherapy
Subject who has received prior pelvic irradiation or is scheduled for pelvic nodal irradiation
Previous pelvic radiation for prostate cancer.
Prior pelvic radiotherapy or prostatectomy
Radiation to spine/pelvis bone or chemoradiation to pelvic organs
Plans for pelvic radiation while participating in the study
Previous pelvic radiation for prostate cancer.
Previous pelvic radiation
Patients with any prior pelvic radiation therapy.
Previous pelvic radiotherapy
Prior pelvic or abdominal radiation
Clinically large pelvic masses reaching above the umbilicus
Patients who have received prior prostate or pelvic radiotherapy, including external beam or brachytherapy
Pelvic organ prolapse greater than stage II
Prior reconstructive pelvic surgery involving mesh for prolapse
Patients who have previously been treated with talimogene laherparepvec, any other oncolytic virus or pelvic radiation are ineligible
Histological or cytological confirmation of locally recurrent or metastatic rectal adenocarcinoma\r\n* Note: Patients with locally recurrent/persistent disease within the pelvis after primary therapy (chemotherapy, surgery, and/or radiotherapy) are eligible\r\n* Note: Patients who have had prior pelvic radiotherapy with a total dose of =< 54 Gy are eligible\r\n* Note: Patients with or without metastatic disease (excluding untreated central nervous system [CNS] metastasis), with primary pelvic disease or pelvic recurrence are eligible\r\n* Note: Patients with pelvic disease that is potentially resectable or unresectable are eligible
Patient has received any pelvic radiotherapy (including external beam and/or brachytherapy).
No prior pelvic radiotherapy, chemotherapy, immunotherapy, or other anti-cancer treatment for rectal cancer
Previous radiotherapy in the pelvic region (eg, prostate) or previous rectal surgery (eg, total mesorectal excision [TME]) or any investigational treatment for rectal cancer
Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption
Has received any pelvic radiotherapy (including external beam and/or brachytherapy.)
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Previous pelvic irradiation therapy
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Patients who have received previous vaginal, pelvic, or abdominal irradiation
Prior history of abdominal irradiation; patients who have received prior pelvic radiation for colorectal cancer are eligible; however, prior radiation treatment plans must be reviewed prior to enrollment
Prior pelvic radiation
Rectal cancer staged as T4 by pelvic MRI
Patients who have had pelvic or abdominal radiation therapy.
Previous pelvic irradiation, prostate brachytherapy
Eligible patients should not have had previous pelvic radiotherapy, chemotherapy or surgery for prostate cancer
Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis
Previous pelvic RT
Prior pelvic radiotherapy
Previous pelvic radiation affecting >= 25% of the bone marrow; patients who received whole pelvic radiation are excluded
Patients who had pelvic radiation within 12 months
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
History of abdominal/pelvic radiation therapy
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Patients with any prior chemotherapy or radiotherapy for pelvic malignancy
Previous pelvic radiation or prostate brachytherapy
Candidate for pelvic or pelvic-inguinal radiotherapy and concurrent chemotherapy; patients undergoing preoperative chemoradiotherapy are excluded
Prior history of hip, pelvic, or lumbosacral prosthesis or other implanted device
Patient with any prior chemotherapy or radiotherapy for pelvic malignancy
Previous pelvic radiation for prostate cancer
Patient with any prior chemotherapy or radiotherapy for pelvic malignancy
Previous chemotherapy or pelvic radiation therapy
No prior pelvic radiation
Tumour stage cT1-T3abN0 based on pelvic MRI
cN0 stage based on pelvic MRI. Any nodes ? 10 mm in longest dimension are considered malignant, regardless of nodal morphology. For pelvic nodes < 10 mm in longest dimension, if nodes are seen and are deemed to be morphologically benign in the opinion of the radiologist and surgeon, the patient is eligible. Patients with visible pelvic sidewall nodes are excluded
Previous pelvic radiation for any reason.
Completion of pelvic radiotherapy treatment for this current rectal cancer or any prior pelvic radiotherapy (e.g., prior prostate or cervical cancer therapy).
Prior pelvic radiotherapy
Has known distant metastases; clinically involved pelvic nodes (N1-N3) are allowed
Prior pelvic radiation
Subjects who have a solitary central pelvic recurrence which can be curatively resected
Any therapeutic pelvic radiation
Subjects must not have had prior pelvic radiation therapy
History of prior pelvic radiation therapy
No prior pelvic radiation therapy or chemotherapy
No prior pelvic radiotherapy
Patients must be considered able to tolerate systemic chemotherapy combined with pelvic radiation therapy, and radical cystectomy
Previous systemic chemotherapy (for any cancer) or pelvic radiation therapy
Previous pelvic radiation for bladder or prostate cancer if performed < 12 months prior to enrollment into the study
Patients with a history of pelvic irradiation for any reason
Patients who have received previous pelvic or abdominal radiation, cytotoxic chemotherapy, or previous therapy of any kind for this malignancy or any pelvic or abdominal radiation for any prior malignancy
Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields
Patients who have received prior pelvic irradiation are not eligible
Received prior chemotherapy for any abdominal or pelvic tumor.
Current or prior pelvic external beam radiotherapy within 5 years of entry
Patients who have received prior chemotherapy for any abdominal or pelvic tumor (other than ovarian, fallopian tube, and primary peritoneal) are excluded
Any previous pelvic radiotherapy
Patients must not have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.
Subject who has undergone a prior pelvic anastomosis.
Subject with an active abdominal or pelvic infection at the operation site.
Patients must be planned to receive whole pelvic radiotherapy to a total dose of 45 Gy or greater
Patients who received prior pelvic radiotherapy for any indication
History of any major rectal or pelvic surgery or radiotherapy
No previous history of pelvic radiation
Patients with a history of prior whole pelvic radiation
Pelvic radiation therapy
Previous pelvic radiotherapy that would prevent prostate/seminal vesicle (SV) irradiation
Patients who have received prior pelvic radiation
Previous pelvic radiotherapy
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Prior history of pelvic radiation therapy
History of prior chemotherapy or pelvic irradiation
No history of previous pelvic irradiation
History of prior pelvic irradiation
Patient has received any pelvic radiotherapy (including external beam and/or brachytherapy.)
Refuses or is unable to have pelvic MRI
Subjects who have had previous pelvic radiotherapy or have had chemotherapy or surgery for prostate cancer
Prior history of pelvic radiotherapy
Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis
Previous pelvic radiation for prior cancer
Previous pelvic radiation therapy
Prostate pelvic radiation within the past 12 months
Prior pelvic radiation therapy
Patients with isolated recurrences (vaginal, pelvic, or para-aortic) that are amenable to potentially curative treatment with radiation therapy or surgery
Recommended to undergo pelvic irradiation with concurrent chemotherapy
An oncology research protocol requiring full pelvic radiation (i.e., 4-field box technique)
Patient must not have had radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Prior abdomino-pelvic irradiation
Patients who have received previous vaginal, pelvic, or abdominal irradiation
Prior pelvic irradiation.
For abdominal or pelvic irradiation: active inflammatory bowel disease
No history of previous chemotherapy or pelvic irradiation
History of prior chemotherapy or pelvic irradiation
Documented distant metastatic disease; but pelvic lymphoadenopathy is NOT excluded
History of pelvic radiation
E 03. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of bone marrow.
Patients must not have undergone a prior partial cystectomy for invasive bladder cancer; patients must not have received any prior pelvic surgery that would obviate a complete extended lymphadenectomy (e.g. aorto-femoral/iliac bypass) or for whom the surgeon feels that their ability to perform a standard or extended pelvic node dissection would be compromised
Patients must not have received any prior pelvic irradiation
Patients must be considered able to tolerate systemic chemotherapy and pelvic radiation therapy
Previous pelvic radiation therapy
Pelvic osseous tumors ANY SIZE
Acute pelvic inflammatory disease
Patients with a history of pelvic or abdominal radiotherapy;
Patients must be at least 6 weeks out from pelvic irradiation, and must not have more than 10% of bone marrow irradiated.
Has received and completed a course of pelvic radiotherapy ? 6 months prior to LAR surgery (Day 0).
Candidate for pelvic, pelvic-inguinal, or extended field radiotherapy with or without concurrent chemotherapy; patients undergoing preoperative or adjuvant chemotherapy are excluded
Radiation therapy to more than 25% of the bone marrow (note: whole pelvic radiation is considered to be over 25%)
Previous pelvic irradiation, prostate brachytherapy
Have had previous radiation of the pelvic area
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
No prior radiation to bladder or pelvic region
Patients who have isolated recurrences (vaginal, pelvic, or paraaortic) that are amenable to potentially curative treatment with radiation therapy or surgery
Patients who have pelvic irradiation with doses ? 45 Grays (Gy).
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Prior pelvic external beam radiotherapy (EBRT)
Prior history of pelvic irradiation
History of extensive prior pelvic irradiation.
Patients with any prior history of whole pelvic radiation therapy (WPRT)
Patients who have had previous pelvic radiation treatment
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Patients with any prior pelvic surgery
Patients with prior history of pelvic fractures or hip replacement
Large pelvic or intra-abdominal masses
Participants with a history of pelvic irradiation; or chemotherapy or radiotherapy within the preceding 14 days
Patients must have had a pelvic MRI within 28 days prior to the initiation of treatment
History of previous abdominal or pelvic radiation therapy
Prior breast, chest or pelvic radiotherapy
Patients undergoing pelvic exenteration
History of pelvic radiation
Current diagnosis of a gastrointestinal, abdominal, or pelvic cancer for which the use of continuous definitive or adjuvant external-beam radiation therapy (RT) to the abdomen or pelvis to a minimum dose of 4500 cGy is planned
Prior abdominal or pelvic RT
Radiotherapy within 28 days and abdominal/pelvic radiotherapy within 60 days prior to Day 1 of Cycle 1
Patients cannot have previously received pelvic external beam radiation or brachytherapy; patients may be enrolled while undergoing vaginal brachytherapy radiation treatment
Patients who have received prior pelvic external beam radiation or brachytherapy will be excluded
History of prior abdominal or pelvic radiation
Previously undergone major pelvic surgery
Prior pelvic radiation
Prior pelvic RT
Known or suspected active pelvic infection
Patients with prior abdominal or pelvic surgery
Major abdominal or pelvic surgery within the past 6 months
Prior pelvic radiation for any reason
History of pelvic or rectal radiation therapy
Subjects with previous pelvic or abdominal radiation therapy;
Patients who have received any prior pelvic radiation therapy in the area of the tumor that precludes the delivery of a curative dose of pelvic radiation
Willingness to undergo pelvic radiotherapy
Contraindications to radiotherapy (including active inflammatory bowel disease or prior pelvic radiation therapy [XRT])
Extra-pelvic metastasis on any imaging or biopsy.
Prior pelvic external beam radiation therapy (RT).
SUB-STUDY I: Prior pelvic external beam radiation therapy or brachytherapy
SUB-STUDY II: Prior pelvic external beam radiation therapy or brachytherapy
Prior pelvic radiation
Prior pelvic external beam radiation therapy or brachytherapy
No prior pelvic radiotherapy
Patients who are referred with pelvic symptoms, a known pelvic mass, or a history of prior radiation, will be excluded from this investigation
Patients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than 10 years as determined by treating physician
Prior pelvic surgery or radiation
Prior pelvic irradiation
History of prior pelvic radiation
Prior hip replacement or other major pelvic surgery
Prior history of pelvic radiotherapy
Prior history of pelvic radiation
Past history of pelvic radiotherapy
subjects with any contraindication to pelvic radiotherapy including, but not limited to, previous pelvic radiotherapy or brachytherapy
Has received prior pelvic radiation therapy
